Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.42% | -13.01% | -6.78% | -8.49% | -0.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.42% | -13.01% | -6.78% | -8.49% | -0.29% |
| Cost of Revenue | -0.07% | -15.39% | -16.22% | -16.64% | -15.59% |
| Gross Profit | -8.75% | -12.91% | -6.38% | -8.14% | 0.42% |
| SG&A Expenses | 0.37% | -4.89% | -2.90% | 8.71% | -4.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.18% | -5.11% | -5.00% | 3.15% | -9.89% |
| Operating Income | -50.60% | -49.41% | -15.53% | -54.92% | 108.84% |
| Income Before Tax | 116.40% | 121.73% | 130.17% | -451.03% | -804.19% |
| Income Tax Expenses | -66.27% | -59.20% | -37.52% | -36.43% | 23.08% |
| Earnings from Continuing Operations | 111.06% | 114.66% | 120.94% | -742.29% | -2,583.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 34.49% | 43.60% | 22.00% | 38.62% | -18.20% |
| Net Income | 104.84% | 108.27% | 113.00% | -2,033.69% | -3,059.62% |
| EBIT | -50.60% | -49.41% | -15.53% | -54.92% | 108.84% |
| EBITDA | -42.96% | -44.57% | -12.45% | -51.02% | 98.02% |
| EPS Basic | 104.02% | 106.98% | 111.36% | -1,827.29% | -12,447.42% |
| Normalized Basic EPS | 22.86% | 213.61% | 783.44% | -130.89% | -7.55% |
| EPS Diluted | 101.24% | 101.55% | 103.66% | -3,080.67% | -25,988.00% |
| Normalized Diluted EPS | 631.91% | 598.00% | 322.16% | -172.04% | -130.72% |
| Average Basic Shares Outstanding | 13.85% | 21.38% | 29.26% | 28.55% | 59.84% |
| Average Diluted Shares Outstanding | 10.39% | 17.96% | 27.19% | 26.53% | 60.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |